- Home
- TKLF vs NRSN Comparison
TKLF vs NRSN Comparison
Compare TKLF & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKLF
- NRSN
- Stock Information
- Founded
- TKLF 2006
- NRSN 2017
- Country
- TKLF Japan
- NRSN Israel
- Employees
- TKLF N/A
- NRSN N/A
- Industry
- TKLF Other Specialty Stores
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- TKLF Consumer Discretionary
- NRSN Health Care
- Exchange
- TKLF Nasdaq
- NRSN Nasdaq
- Market Cap
- TKLF 16.0M
- NRSN 58.8M
- IPO Year
- TKLF 2022
- NRSN 2021
- Fundamental
- Price
- TKLF $3.71
- NRSN $1.91
- Analyst Decision
- TKLF
- NRSN Buy
- Analyst Count
- TKLF 0
- NRSN 2
- Target Price
- TKLF N/A
- NRSN $14.00
- AVG Volume (30 Days)
- TKLF 11.0K
- NRSN 442.8K
- Earning Date
- TKLF 07-15-2025
- NRSN 07-11-2025
- Dividend Yield
- TKLF N/A
- NRSN N/A
- EPS Growth
- TKLF N/A
- NRSN N/A
- EPS
- TKLF 1.70
- NRSN N/A
- Revenue
- TKLF $219,520,631.00
- NRSN N/A
- Revenue This Year
- TKLF N/A
- NRSN N/A
- Revenue Next Year
- TKLF N/A
- NRSN N/A
- P/E Ratio
- TKLF $2.18
- NRSN N/A
- Revenue Growth
- TKLF 32.02
- NRSN N/A
- 52 Week Low
- TKLF $2.20
- NRSN $0.51
- 52 Week High
- TKLF $8.53
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- TKLF 51.46
- NRSN 51.18
- Support Level
- TKLF $3.20
- NRSN $2.04
- Resistance Level
- TKLF $3.85
- NRSN $2.35
- Average True Range (ATR)
- TKLF 0.20
- NRSN 0.25
- MACD
- TKLF -0.02
- NRSN -0.04
- Stochastic Oscillator
- TKLF 60.93
- NRSN 28.74
About TKLF Yoshitsu Co. Ltd
Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores; Online Stores and Services; and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from China followed by Japan and other overseas markets.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.